Merck tops quarterly estimates, hikes profit outlook as new Keytruda form shows strength

Merck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.

Published on RocksNews

29 Oct 2026, 11:09 UTC

Updated

29 Oct 2026, 11:09 UTC

Language

English